Company: NCEL
Filing Date: 2025-02-10
Form Type: 425
Source: 0001213900-25-011502
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: 425
Chunk 4
---
,
patient-centric care, and long-term value creation. As we move forward, NLS and Kadimastem are dedicated to ensuring a smooth integration
process that maximizes the potential of both organizations—bringing together expertise, resources, and vision to improve the lives
of patients impacted by diabetes and related conditions.

Safe Harbor Statement

This press release contains expressed or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements
when they discuss the expected closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their
respective shareholders, including value creation for shareholders, the expected strategic position of the combined company following
the merger, if completed and the expected benefits of DOXA in the treatment of diabetes. These forward-looking statements and their implications
are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies’
ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the
closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder
approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or
changes to business relationships resulting from the announcement or completion of the merger; changes in technology and market requirements;
either or both companies may encounter delays or obstacles in launching and/or successfully completing their clinical trials; the companies’
products may not be approved by regulatory agencies; their technologies may not be validated as they progress and their methods may not
be accepted by the scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge
is essential to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by
the companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally
good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; the
companies’ patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact either
or both of the